Compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with lower risks of cardiac death and composite renal outcomes without ...

Following a lower limb revascularization, rivaroxaban (Xarelto; Bayer/Janssen) added to daily aspirin is better than aspirin alone for reducing the risk of first and total limb and CV events, a ...

Myocardial injury after non-cardiac surgery (MINS) is common. We investigated the incidence and outcomes of MINS, and mechanistic underpinnings using pre-operative whole blood gene expression ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced ...

Peripheral arterial disease (PAD) is a common complication of type 2 diabetes mellitus (T2DM) and an independent cardiovascular risk factor 1. Diabetic patients with PAD have poorer quality of life ...

A new study reveals diminished quality of life among patients with chronic limb-threatening ischemia, a severe form of peripheral artery disease, and emphasizes the benefits of revascularization on ...

WASHINGTON, DC—In patients with chronic limb-threatening ischemia (CLTI), delays longer than 30 days from the time of diagnosis to initiation of endovascular revascularization are associated with an ...

WASHINGTON (January 9, 2024) – Proceedings from an expert consensus roundtable that discussed the benefits of intravascular ultrasound (IVUS) in lower extremity revascularization procedures were ...

Please provide your email address to receive an email when new articles are posted on . In patients with peripheral artery disease who had revascularization, major adverse limb events were higher in ...

Risk of recurrent major adverse limb events was lower in diabetes patients taking GLP-1 agents compared with DPP-4 inhibitors. Reduction of limb events was most significant for major amputations, ...